8-K: Paysign Q2 2025 Revenue Jumps 33% on Pharma Growth

Paysign, Inc. reported record second quarter 2025 revenues of $19.08 million, a 33.1% increase year-over-year, driven by strong growth in its pharma patient affordability business.

Summary

• Total revenues for the second quarter of 2025 reached $19.08 million, marking a 33.1% increase compared to the second quarter of 2024.
• Net income for Q2 2025 was $1.39 million, a 99.1% increase from $697 thousand in the prior year, resulting in diluted earnings per share of $0.02.
• Adjusted EBITDA for Q2 2025 more than doubled to $4.51 million, up 101.8% from $2.24 million a year ago, with diluted Adjusted EBITDA per share at $0.08.
• Pharma patient affordability revenue surged by 189.9%, adding seven net programs and exiting the quarter with 97 active programs, with processed claims increasing over 80%.
• Plasma revenue decreased by 4.7% year-over-year, primarily due to reduced revenue per plasma center and an industry-wide oversupply, despite adding 123 net plasma centers.
• Gross profit increased by 55.0% to $11.76 million, with gross profit margin expanding by nine percentage points to 61.6%.
• The company exited the quarter with $11.8 million of unrestricted cash and zero bank debt.
• Gross dollar load volume and gross spend volume were down 3.7% and 6.3% respectively over Q2 2024.

Sentiment

Score: 8

Explanation: The company reported strong financial results, with significant revenue, net income, and Adjusted EBITDA growth, primarily driven by its rapidly expanding pharma patient affordability business. Despite challenges in the plasma segment, the overall performance and upward revision of full-year guidance indicate robust operational execution and positive future prospects.

Positives

• Achieved record quarterly revenue of $19.08 million, representing a 33.1% increase year-over-year.
• Net income nearly doubled to $1.39 million, up 99.1% from the same period last year.
• Adjusted EBITDA more than doubled to $4.51 million, an increase of 101.8% year-over-year.
• Pharma patient affordability revenue grew by an impressive 189.9%, adding seven net programs and expecting 30-40 more by year-end.
• Gross profit margin expanded significantly by nine percentage points to 61.6%, demonstrating improved profitability.
• Exited the quarter with $11.8 million of unrestricted cash and zero bank debt, indicating strong liquidity.
• Successfully onboarded 123 new plasma centers in record time, demonstrating operational efficiency.
• Demonstrated operating leverage with expanded operating, net, and Adjusted EBITDA margins.
• Revised full-year 2025 estimated results upward, reflecting confidence in continued growth.

Negatives

• Plasma revenue decreased by 4.7% year-over-year, primarily due to an industry-wide oversupply in plasma inventories.
• Average monthly revenue per plasma center decreased to $7,098 compared to $7,916 for the same period last year.
• Gross dollar load volume and gross spend volume were down 3.7% and 6.3% respectively over Q2 2024.
• Absorbed approximately $300,000 in one-time expenses tied to the late-quarter onboarding of 123 plasma centers.
• A customer informed the company of the closing of 22 underperforming plasma centers scheduled for August 15.
• Increased cost of revenues, including customer care expense (up 47.0%), third-party program management fees (up 99.9%), plastics, collateral, and postage (up 80.7%), and sales and commission expense (up 169.4%).
• Other income decreased by $208 thousand, partly due to implied interest expense related to the Gamma acquisition.
• The effective tax rate for the second quarter was 32.1%, higher than 25.8% in the prior year, due to discrete items related to stock price appreciation.

Risks

• Inability to continue the current growth rate in future periods.
• A downturn in the economy, including as a result of COVID-19 and variants, as well as further government stimulus measures, could reduce the customer base and demand for products and services, adversely affecting business, financial condition, profitability, and cash flows.
• Operating in a highly regulated environment.
• Failure by the company or business partners to comply with applicable laws and regulations.
• Changes in laws, regulations, credit card association rules, or other industry standards affecting the business.
• A data security breach could expose the company to liability and protracted and costly litigation.
• Other risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company revised its full-year 2025 estimated results upward, expecting total revenues in the range of $76.5 million to $78.5 million, reflecting year-over-year growth of 32.7% at the midpoint. Plasma revenue is estimated to be approximately 56% of total revenue (flat year-over-year growth), while pharma patient affordability revenue is expected to make up approximately 40.5% of total revenue (over 145% year-over-year growth). Full-year gross profit margins are projected between 61.0% and 62.0%. Net income is expected to be between $6.0 million and $7.0 million, or $0.10 to $0.12 per diluted share, and Adjusted EBITDA is anticipated to be in the range of $18.0 million to $20.0 million, or $0.31 to $0.35 per diluted share. For Q3 2025, total revenue is expected to be $19.5 million to $20.5 million, with plasma revenues at approximately 60% and pharma patient affordability at approximately 37% of revenue, and gross profit margins around 59%.

Management Comments

• Mark Newcomer, President and CEO: "Q2 2025 was a milestone quarter for Paysign. We achieved record quarterly revenue of $19.1 million, expanded gross margins and more than doubled adjusted EBITDA to $4.5 million versus the same period last year. Net income rose 99% to $1.4 million, even after absorbing approximately $300,000 in one-time expenses tied to the late-quarter onboarding of 123 plasma centers."
• Mark Newcomer, President and CEO: "Our pharma patient affordability business grew revenue by an impressive 190%, exiting the quarter with 97 active programs while expecting an additional 30-40 programs to be added prior to year end, underscoring the strong demand for our solutions. We continue to attract larger pharmaceutical programs as we continue to demonstrate the value of our solutions to the pharmaceutical industry while maintaining a robust pipeline. We are highly confident that this momentum will sustain our strong growth trajectory well into the future."
• Mark Newcomer, President and CEO: "Looking ahead, we are executing on strategic initiatives to expand our plasma offerings with our suite of SaaS donor engagement technologies and scale operations to meet accelerating demand for our pharma patient affordability solutions. To this end, we are planning to open a new, state-of-the-art patient services contact center in the third quarter. This facility will increase our support capacity fourfold, ensuring our ability to effectively scale operations to meet the rapidly growing demand we are experiencing. With momentum building across plasma, pharma patient affordability, and broader healthcare markets, we are well-positioned to deliver lasting value for both our clients and shareholders."
• Jeff Baker, CFO: "We delivered another quarter of solid operating results with our pharma patient affordability business leading the way, representing 40.6% of revenue, a significant increase from the 18.7% of revenue it contributed during the same period last year. This continues to help offset the decline we are experiencing in plasma due largely to an industry-wide oversupply of plasma inventories."
• Jeff Baker, CFO: "Also helping offset the weakness in plasma was a very good win from one of our existing customers who decided to move their remaining 132 plasma locations to us with the first 123 moving on June 16 and the remaining nine moving July 21. We were also informed by a customer of the closing of 22 underperforming centers scheduled for August 15. We believe the majority of the impacted donors will likely continue to donate at nearby centers. This customer has also informed us that they plan to open eight new centers before July 2026, and an additional eight in the following 12-month period."
• Jeff Baker, CFO: "Despite the upfront costs to onboard these centers in record time, we continued to expand our gross profit margins by 8.7%, or 870 basis points (bps), our operating margin by 6.7%, or 670 bps, our net margin by 2.4%, or 240 bps, and our Adjusted EBITDA margin by 8.1%, or 810 bps, demonstrating the operating leverage inherent in our business model."
• Jeff Baker, CFO: "With the results of our second quarter of 2025 now in the books, the new plasma centers coming into the mix, and the strong pipeline we have in our pharma patient affordability business, we are revising our full-year 2025 estimated results upward."
• Jeff Baker, CFO: "For the third quarter of 2025, we expect total revenue to be in the range of $19.5 million to $20.5 million, reflecting continued strength for our pharma patient affordability business and the contribution of the new plasma centers to our plasma business. We expect plasma revenues to be approximately 60% of revenue and pharma patient affordability to be approximately 37% of revenue. Gross profit margins are expected to be approximately 59% due to the higher mix of plasma revenue and impact from startup costs related to the new patient services contact center. Operating expenses are expected to be between $10.5 million and $11.5 million, of which depreciation and amortization will be approximately $2.2 million and stock-based compensation will be approximately $1.4 million. Adjusted EBITDA is expected to be in the range of $4.5 million to $5.0 million, or approximately 23.1% to 24.4% of revenue."

Industry Context

The company's performance reflects a divergence in its key markets. The plasma industry is currently experiencing an oversupply of inventories, which has negatively impacted Paysign's plasma revenue and average revenue per center. This trend is partially offset by strategic wins in onboarding new plasma centers. In contrast, the pharma patient affordability market is demonstrating robust demand and significant growth, which Paysign is effectively leveraging. The company's focus on expanding its pharma offerings and investing in infrastructure like a new patient services contact center aligns with capitalizing on this high-growth segment, while also seeking to enhance its plasma offerings with SaaS donor engagement technologies to navigate industry challenges.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and upward revised guidance, potentially leading to increased share value.
• Customers (Pharma): Enhanced support capacity with a new contact center, ensuring better service for rapidly growing demand.
• Customers (Plasma): While some centers are closing, the company is onboarding new centers and expanding SaaS donor engagement technologies, aiming to improve offerings and donor engagement.
• Employees: Continued hiring to support the company's growth, particularly in the pharma patient affordability business, and increased benefit costs.

Next Steps

• Open a new, state-of-the-art patient services contact center in the third quarter of 2025 to increase support capacity fourfold.
• Add an additional 30-40 pharma patient affordability programs prior to year-end 2025.
• An existing customer plans to open 8 new plasma centers before July 2026.
• An existing customer plans to open an additional 8 new plasma centers in the 12-month period following July 2026.

Key Dates

Recommendation

Paysign's Q2 2025 results demonstrate exceptional growth in its high-margin pharma patient affordability segment, which is effectively offsetting declines in the plasma business. The company achieved record revenues, nearly doubled net income and Adjusted EBITDA, and significantly expanded gross margins. Management's upward revision of full-year guidance, coupled with strategic investments in a new patient services contact center and a robust pipeline for pharma programs, indicates strong future growth potential and operational leverage. The zero bank debt and healthy unrestricted cash position further strengthen the investment case, suggesting a strong buy for investors seeking growth in the fintech and healthcare payments space.

Keywords

Prepaid card programs, Pharma patient affordability, Financial technology, Integrated payment processing, Plasma centers, Healthcare industry, Fintech, Payment platform, Corporate rewards, Donor compensation, Copay assistance, Earnings report, SEC filing